Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Frankrijk
  4. Euronext Paris
  5. Valneva SE
  6. Nieuws
  7. Persberichten
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Rapport
Real Time Euronext Paris  -  17:39:37 27-01-2023
6.436 EUR   +1.96%
03/01Valneva SE rapporteert verdere Heterologe Booster-gegevens van verkennende, kleine klinische studie voor haar geïnactiveerde COVID-19 vaccin, VLA2001.
CI
02/01Valneva's COVID-19 boosterschot toont slechts een marginaal hogere neutraliserende antilichaamrespons.
MT
2022Sectorupdate: Gezondheidszorgaandelen gemengd op vrijdag premarket
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť VALNEVA SE
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
GL
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
AQ
2022Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Ca..
GL
2022Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Ca..
AQ
2022Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and O..
GL
2022Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and O..
AQ
2022Valneva : Advances in the development of a single-shot live-attenuated chikungunya vaccine..
PU
2022Valneva : Whole-cell inactivated platforms (Valneva Breakfast Symposium Presentation at th..
PU
2022Valneva Hosts Investor Day in New York City
GL
2022Valneva Hosts Investor Day in New York City
AQ
2022Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya..
GL
2022Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya..
AQ
2022Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo..
GL
2022Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo..
AQ
2022Valneva to Host Investor Day in New York City
GL
2022Valneva to Host Investor Day in New York City
AQ
2022Valneva Appoints Dipal Patel as Chief Commercial Officer
GL
2022Valneva Appoints Dipal Patel as Chief Commercial Officer
AQ
2022Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
GL
2022Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
AQ
2022Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Confer..
GL
2022Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Confer..
AQ
2022Chikungunya : Phase 3 Clinical Development of a Single-shot Live-Attenuated Vaccine (Prese..
PU
2022One Step Closer To A Chikungunya Vac : update on Valneva's live-attenuated vaccine candida..
PU
2022One Step Closer To A Chikungunya Vac : update on Valneva's live-attenuated vaccine candida..
PU
2022Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientif..
GL
2022Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientif..
AQ
2022Valneva Announces Closing of Upsized Ä102.9 Million Global Offering
GL
2022Valneva Announces Closing of Upsized Ä102.9 Million Global Offering
AQ
2022Valneva : Document AMF CP. 2022E864499
PU
2022Valneva : Document AMF CP. 2022E864246
PU
2022Valneva Announces Pricing of Ä102.9 Million Global Offering of American Depositary Shar..
GL
2022Valneva Announces Pricing of Ä102.9 Million Global Offering of American Depositary Shar..
GL
2022Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of ..
GL
2022Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of ..
GL
2022Valneva Provides Further Update on its COVID-19 Activities
GL
2022Valneva Provides Further Update on its COVID-19 Activities
GL
2022Valneva : Document AMF CP. 2022E862347
PU
2022Valneva : Document AMF CP. 2022E861835ANN
PU
2022Valneva : Document AMF CP. 2022E861835
PU
2022Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
GL
2022Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
AQ
2022Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution o..
AQ
2022Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution o..
GL
2022Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infect..
GL
2022Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infect..
AQ
2022Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Boos..
GL
2022Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Boos..
AQ
2022Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
GL
2022Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
AQ
2022Valneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
GL
2022Valneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
AQ
2022Valneva Provides Update on IXIAROģ Supply Contract with U.S. Department of Defense
GL
2022Valneva Provides Update on IXIAROģ Supply Contract with U.S. Department of Defense
AQ
2022Valneva : Establishes an At-the-Market (ATM) Program on Nasdaq - Form 6-K
PU
2022Valneva Establishes an At-the-Market (ATM) Program on Nasdaq
GL
2022Valneva Establishes an At-the-Market (ATM) Program on Nasdaq
AQ
2022Valneva : Reports H1 2022 Results and Provides Corporate Updates - Form 6-K
PU
2022Valneva : EXPLANATORY NOTE - Form 6-K/A
PU
2022Valneva : 2022 Half-Year Report
PU
2022Valneva Reports H1 2022 Results and Provides Corporate Updates
GL
2022Valneva Reports H1 2022 Results and Provides Corporate Updates
AQ
2022Valneva : Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA1..
PU
2022Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
GL
2022Major test of first possible Lyme vaccine in 20 years begins
AQ
2022Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
AQ
2022Valneva : Confirms Amendment of Advance Purchase Agreement with European Commission for Va..
PU
2022Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for V..
GL
2022Valneva SE - European Commission Approves Purchase Agreement Amendment for Valneva's In..
AQ
2022Valneva : European Commission Approves Purchase Agreement Amendment for Valneva's Inactiva..
PU
2022European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COV..
GL
2022European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COV..
AQ
2022Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19..
AQ
2022Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19..
GL
2022EMA recommends Valneva's COVID-19 vaccine for authorisation in the EU
AQ
1  2  3  4  5  6  7  8  9  10Volgende